Please log in to get access to this content
Dr. Enrique Grande discusses the findings of the EV-302 trial of enfortumab vedotin plus pembrolizumab and the CheckMate 901 trial of nivolumab plus chemotherapy, both conducted in the advanced urothelial cancer setting.
Speaker
- Dr. Enrique Grande
MD Anderson Cancer Center Madrid, Spain